157 related articles for article (PubMed ID: 12856363)
1. [Gastrointestinal stromal tumors: a new model for target therapy].
Tonini G; Vincenzi B; La Cesa A
Clin Ter; 2003; 154(2):75-6. PubMed ID: 12856363
[No Abstract] [Full Text] [Related]
2. [Tyrosine kinase inhibitor as a targeted therapy for GIST tumors].
Joensuu H
Duodecim; 2002; 118(22):2305-12. PubMed ID: 12523107
[No Abstract] [Full Text] [Related]
3. Current management of GIST.
Blanke C
Clin Adv Hematol Oncol; 2004 May; 2(5):280, 283. PubMed ID: 17682286
[No Abstract] [Full Text] [Related]
4. [Targeted therapies in soft-tissue and visceral sarcomas].
Emile JF
Ann Pathol; 2009 Nov; 29 Spec No 1():S81-2. PubMed ID: 19887262
[No Abstract] [Full Text] [Related]
5. Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.
de Jong FA; Verweij J
Expert Rev Anticancer Ther; 2003 Dec; 3(6):757-66. PubMed ID: 14686698
[TBL] [Abstract][Full Text] [Related]
6. [Gastrointestinal stromal tumors].
Schlemmer M; Milani V; Tschoep K; Fahn W; Wendtner CM
Dtsch Med Wochenschr; 2003 Sep; 128(39):2015-9. PubMed ID: 14508696
[No Abstract] [Full Text] [Related]
7. [STI571 and gastro intestinal stromal tumors].
Ray-Coquard I; Cesne AL; Blay JY
Bull Cancer; 2001 Jul; 88(7):661-2. PubMed ID: 11495818
[No Abstract] [Full Text] [Related]
8. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.
Demetri GD
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1115-24. PubMed ID: 12512386
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal stromal tumour--a paradigm shift in management of solid tumours.
Bapsy PP; Prabhash K; Babu KG; Girish MH
J Assoc Physicians India; 2003 Aug; 51():801-4. PubMed ID: 14651144
[TBL] [Abstract][Full Text] [Related]
10. Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation.
Wakai T; Kanda T; Hirota S; Ohashi A; Shirai Y; Hatakeyama K
Br J Cancer; 2004 Jun; 90(11):2059-61. PubMed ID: 15150562
[TBL] [Abstract][Full Text] [Related]
11. [At last, an effective therapy for non-differentiated GI sarcomas (gastro intestinal stromal tumor)].
Des Guetz G; De Mestier P; Pierga JY
J Chir (Paris); 2002 Oct; 139(5):268-73. PubMed ID: 12410126
[TBL] [Abstract][Full Text] [Related]
12. [Gastrointestinal stromal tumors: open problems].
Peparini N; Maturo A
G Chir; 2002 Oct; 23(10):357-9. PubMed ID: 12611255
[No Abstract] [Full Text] [Related]
13. [Target-based therapy against gastrointestinal stromal tumors--from molecular diagnosis to molecular target therapy].
Nishida T; Yasumasa K
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1071-8. PubMed ID: 12938260
[TBL] [Abstract][Full Text] [Related]
14. [New oncological treatment principle with imatinib].
Kuenen BC; Pinedo HM
Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2044-5. PubMed ID: 14606348
[TBL] [Abstract][Full Text] [Related]
15. Imatinib as a paradigm of targeted therapies.
Druker BJ
Adv Cancer Res; 2004; 91():1-30. PubMed ID: 15327887
[TBL] [Abstract][Full Text] [Related]
16. Current clinical management of gastrointestinal stromal tumors.
Tosoni A; Nicolardi L; Brandes AA
Expert Rev Anticancer Ther; 2004 Aug; 4(4):595-605. PubMed ID: 15270663
[TBL] [Abstract][Full Text] [Related]
17. [Gastrointestinal stromal tumors. Current data].
Arfaoui D; Yacoubi MT; Elloumi H; Frikha F; Mokni M; Ajmi S
Tunis Med; 2003 Dec; 81(12):907-13. PubMed ID: 14986524
[TBL] [Abstract][Full Text] [Related]
18. [Imatinib, a specific tyrosine-kinase inhibitor, for the treatment of patients with a gastrointestinal stroma cell tumor].
Gelderblom H; Hogendoorn PC; van der Graaf WT; Verweij J
Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2051-5. PubMed ID: 14606351
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors--a review.
Sawaki A; Yamao K
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S44-9. PubMed ID: 15309514
[TBL] [Abstract][Full Text] [Related]
20. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.
Chen LL; Trent JC; Wu EF; Fuller GN; Ramdas L; Zhang W; Raymond AK; Prieto VG; Oyedeji CO; Hunt KK; Pollock RE; Feig BW; Hayes KJ; Choi H; Macapinlac HA; Hittelman W; Velasco MA; Patel S; Burgess MA; Benjamin RS; Frazier ML
Cancer Res; 2004 Sep; 64(17):5913-9. PubMed ID: 15342366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
